Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a ...
Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback